Latest Interviews
Showing 1–8 of 8 transcripts.
Clear all filters- a16z10 min
Disrupt Yourself
The speaker frames the current transition in life sciences as an industrial revolution where biology shifts from artisanal discovery to engineered automation, urging leaders to proactively disrupt themselves before market forces do. Drawing parallels to strategic pivots by Jensen Huang at Nvidia and Steve Jobs with AT&T, the presentation defines corporate survival as a form of social engineering that prioritizes future ecosystems over existing profitability. Ultimately, the event calls for redefining healthcare and entertainment as technology sectors to fundamentally reshape illness prevention and treatment.
- a16z21 min
AI is Industrializing Discovery
The speaker characterizes the current biotech era as an industrial revolution where AI is transforming drug discovery from a bespoke artisanal model into a scalable, engineering-driven process. By overcoming myths regarding biological complexity and data scarcity through techniques like graph convolutions and one-shot learning, companies are achieving accuracy rates of over 90% in biomarker discovery and predicting clinical outcomes with modest incremental gains. This strategic shift promises to slash manufacturing costs for protein therapeutics by up to 90% and reduce trial expenses, creating a critical opportunity for professionals to merge domain expertise with AI skills to industrialize discovery at unprecedented scale.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z35 min
a16z Podcast | What Technology Wants, Needs, Does
Marc Andreessen, Frank Chen, Vijay Pande, Alex Rampell
This panel examined critical regulatory tensions in healthcare and fintech, analyzing how the shift to pay-for-value models and Dodd-Frank risk retention rules create new barriers for startups while enabling regulatory arbitrage. Experts further debated the ethical implications of AI in lending and medicine, highlighting the conflict between opaque deep learning algorithms and existing fair-lending laws alongside the potential for technology to render physical travel obsolete through high-fidelity telepresence. The discussion concluded by projecting how innovations in genomic risk scoring, autonomous logistics, and lab-grown organs will fundamentally reshape social determinants of health and long-term human longevity.
- a16z17 min
a16z Podcast | The Business of Healthcare
Rajeev Singh, Vijay Pande, Sean Duffy
Driven by a projected rise in healthcare spending to 19% of GDP and a critical Type 2 diabetes epidemic, the industry is pivoting toward value-based care models led by firms like Omada and Accolade. These companies differentiate themselves through a hybrid tech-persona approach that pairs digital tools with human coaching, securing competitive moats via longitudinal clinical data rather than traditional patent protections. By rejecting fee-for-service structures in favor of outcomes-based pricing and navigating complex regulatory environments, these organizations aim to establish chronic disease management as a mandatory standard of care for a significant portion of the U.S. population within the next five years.
- a16z14 min
a16z Podcast | The Genetics Of Drug Delivery
Stanford professor Russ Altman leads a data science laboratory that integrates molecular, cellular, and population-level data to optimize drug response and identify previously unknown side effects. By analyzing diverse sources ranging from electronic medical records to web search logs, Altman's team successfully uncovered critical interactions, such as a glucose spike caused by combining paroxetine and pravastatin, and predicted new therapeutic uses for existing cancer drugs. This multi-scale approach, supported by funding from the National Institutes of Health and industry partners like Pfizer and Genentech, aims to replace fragmented clinical trial models with continuous, data-driven surveillance for safer and more effective pharmaceutical development.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.
- a16z24 min
When Biology Moves to Engineering
Positioning biological evolution as a source of accumulated "technical debt," the event frames modern healthcare challenges as engineering problems solvable through AI-driven precision rather than traditional trial-and-error discovery. Key advancements in automated circuit design and behavioral digital therapeutics demonstrate how this shift enables predictable, high-accuracy solutions for complex conditions like cancer and diabetes. Ultimately, the approach seeks to transform medicine by engineering the reversal of aging and optimizing systemic care coordination to move from reactive sick care to proactive health maintenance.